Indications -- Asthma/Allergy Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Asthma/Allergy

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (29)	5/1/2002 3:35:49 PM
From: keokalani'nui	of 86

Tanox, Inc. Announces Positive Preliminary Results in Peanut Trial HOUSTON, May 1 /PRNewswire-FirstCall/ -- Tanox, Inc. (Nasdaq: TNOX - news) today announced positive preliminary results in its Phase 2 peanut allergy clinical trial involving TNX-901. The trial involved 84 patients in 4 dose groups, (0, 150, 300, and 450mg). TNX-901 is an anti-IgE antibody being developed by Tanox to provide protection against reactions to accidental peanut ingestion by individuals with peanut allergy. The primary endpoint, based on an increase in symptom threshold to peanuts by oral food challenge, was met with statistical significance. Further studies are being planned. "Peanut allergy is a growing problem, and we are excited that we may have a method of protecting people from the life-threatening risks of accidental peanut exposure," said Nancy Chang, CEO of Tanox. The detailed results of the study will be published in a medical journal or presented at a medical conference later this year.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next